Inovio Pharmaceuticals (INO) Competitors $1.34 +0.03 (+2.29%) Closing price 04:00 PM EasternExtended Trading$1.34 +0.00 (+0.30%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INO vs. MRNA, CVRX, SGHT, TLSI, INGN, PROF, ELMD, RCEL, LNSR, and PDEXShould you be buying Inovio Pharmaceuticals stock or one of its competitors? The main competitors of Inovio Pharmaceuticals include Moderna (MRNA), CVRx (CVRX), Sight Sciences (SGHT), TriSalus Life Sciences (TLSI), Inogen (INGN), Profound Medical (PROF), Electromed (ELMD), Avita Medical (RCEL), LENSAR (LNSR), and Pro-Dex (PDEX). These companies are all part of the "medical" sector. Inovio Pharmaceuticals vs. Its Competitors Moderna CVRx Sight Sciences TriSalus Life Sciences Inogen Profound Medical Electromed Avita Medical LENSAR Pro-Dex Inovio Pharmaceuticals (NASDAQ:INO) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation. Which has more risk & volatility, INO or MRNA? Inovio Pharmaceuticals has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, Moderna has a beta of 1.84, meaning that its share price is 84% more volatile than the S&P 500. Do analysts prefer INO or MRNA? Inovio Pharmaceuticals presently has a consensus price target of $8.80, indicating a potential upside of 556.72%. Moderna has a consensus price target of $46.61, indicating a potential upside of 45.39%. Given Inovio Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Inovio Pharmaceuticals is more favorable than Moderna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inovio Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60Moderna 4 Sell rating(s) 17 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.04 Is INO or MRNA more profitable? Inovio Pharmaceuticals has a net margin of 0.00% compared to Moderna's net margin of -105.67%. Moderna's return on equity of -28.69% beat Inovio Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Inovio PharmaceuticalsN/A -136.93% -89.99% Moderna -105.67%-28.69%-21.94% Do institutionals & insiders believe in INO or MRNA? 26.8% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 2.3% of Inovio Pharmaceuticals shares are held by insiders. Comparatively, 11.0% of Moderna shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media refer more to INO or MRNA? In the previous week, Moderna had 22 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 26 mentions for Moderna and 4 mentions for Inovio Pharmaceuticals. Moderna's average media sentiment score of 0.74 beat Inovio Pharmaceuticals' score of 0.54 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inovio Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 12 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings and valuation, INO or MRNA? Inovio Pharmaceuticals has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInovio Pharmaceuticals$220K223.35-$107.25M-$3.19-0.42Moderna$3.24B3.83-$3.56B-$8.73-3.67 SummaryModerna beats Inovio Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Inovio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INO vs. The Competition Export to ExcelMetricInovio PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.04M$2.91B$5.52B$9.32BDividend YieldN/A2.46%3.76%4.05%P/E Ratio-0.427.7720.1819.43Price / Sales223.35300.75437.3299.95Price / CashN/A42.3835.5357.53Price / Book0.717.768.235.67Net Income-$107.25M-$55.11M$3.23B$257.51M7 Day Performance-7.59%0.95%-0.01%0.52%1 Month Performance-33.00%8.44%5.61%8.84%1 Year Performance-87.96%-2.38%26.52%14.18% Inovio Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INOInovio Pharmaceuticals4.0771 of 5 stars$1.34+2.3%$8.80+556.7%-88.2%$48.04M$220K-0.42320MRNAModerna4.4301 of 5 stars$32.87-2.3%$46.61+41.8%-74.0%$12.71B$3.24B-3.775,800Analyst ForecastAnalyst RevisionCVRXCVRx3.0523 of 5 stars$7.35+7.6%$14.50+97.3%-26.6%$191.64M$52.87M-3.37160News CoveragePositive NewsSGHTSight Sciences1.6073 of 5 stars$3.70+8.5%$4.10+10.8%-57.3%$191.28M$78.11M-3.78210News CoverageAnalyst ForecastTLSITriSalus Life Sciences2.9853 of 5 stars$4.98+1.8%$10.75+115.9%-9.0%$188.44M$32.14M-4.45106INGNInogen4.2285 of 5 stars$6.71-3.0%$11.00+63.9%-28.7%$180.41M$339.96M-5.831,030PROFProfound Medical2.8917 of 5 stars$5.75-1.0%$11.50+100.0%-37.7%$172.79M$10.68M-4.71150Positive NewsELMDElectromed0.8619 of 5 stars$19.30+1.2%$38.00+96.9%+20.2%$161.85M$61.44M25.73160RCELAvita Medical1.3545 of 5 stars$5.88+3.2%$16.50+180.6%-45.7%$155.41M$64.25M-2.68130Positive NewsLNSRLENSAR1.2914 of 5 stars$12.90-1.0%$15.00+16.3%+150.5%$152.09M$53.49M-2.66110Positive NewsPDEXPro-Dex2.4884 of 5 stars$46.23+2.7%$56.00+21.1%+144.1%$150.71M$53.84M16.51140News CoveragePositive News Related Companies and Tools Related Companies Moderna Alternatives CVRx Alternatives Sight Sciences Alternatives TriSalus Life Sciences Alternatives Inogen Alternatives Profound Medical Alternatives Electromed Alternatives Avita Medical Alternatives LENSAR Alternatives Pro-Dex Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INO) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inovio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inovio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INO Stock Alerts